Opportunities
Active & Upcoming Solicitations
Closed Solicitations
| RPP # | Topic | Description | Submission Due Date |
|---|---|---|---|
| Pre-Solicitation Notice | TACTIC: Threat-Agnostic CBRN TherapeutICs | This solicitation will seek to fund development of therapeutics that treat dysregulated host responses to priority CBRN exposures, enabling effective intervention without rapid threat identification and in delayed-presentation scenarios. BARDA is particularly interested in broadly applicable products that preserve or restore physiological function, mitigate systemic injury, and improve clinical outcomes across multiple CBRN threat categories. | |
| Draft RPP | The New Vaccine Platforms (NVP) Program aims to identify new vaccine platforms for the BARDA medical countermeasure (MCM) portfolio and advance them through a staged capability demonstration to identify technologies that (1) are safe; (2) are effective across multiple infectious disease threats from different pathogen families; and (3) enable efficient development and manufacturing. | ||
| Draft RPP | Protection Before Day One (PBD1) | Through this RPP, BARDA intends to advance promising Before Day One vaccine candidates from preclinical development through manufacturing and clinical evaluation, with emphasis on demonstrating breadth of protection, establishing IND readiness, developing scalable manufacturing processes, and generating clinical evidence supporting seasonal performance and potential pandemic benefit. The ultimate objective is to establish a sustainable seasonal vaccination capability that provides population-level protection before a pandemic begins, complementing subsequent deployment of strain-matched pandemic vaccines. |
| RPP # (Date) | Requirement Topic | Closed Date |
|---|---|---|
| RFI: PBD1 (6/3/2026) | Request for Information: Protection Before Day One Vaccine: Advancing Broadly Protective Seasonal Influenza Vaccines with Pandemic Coverage | 7/29/2026 |
| RFI: BSL4 (7/9/2026) | Request for Information: Biosafety Level 4 Preclinical and Nonclinical Support for Medical Countermeasure Development | 7/24/2026 |
Request for Information: Repurposing Equipment for Drug Delivery | 7/23/2026 | |
| RFI: HiPe (6/16/2026) | Request for Information: High Performance Antigen Diagnostics | 7/17/2026 |
| Request for Information: Advanced Clinical Development and Licensure of an Adjuvanted Egg-based Influenza Vaccine | 7/10/2026 | |
| RPP-26-13-BundiVx (6/11/2026) | Bundibugyo virus Outbreak Response Vaccines (BundiVx) | 7/2/2026 |
| RFI Path(SM) (5/18/2026) | Request for Information: AI-Enabled Discovery of Broad-Spectrum Small-Molecule Inhibitors for Filoviruses | 6/17/2026 |
| RPP-26-12-ARDS (4/28/2026) | Host-Directed Therapeutics for the Prevention of Progression to ARDS | 5/26/2026 |
| RPP-26-10-RAPID (4/15/2026) | Rapid Antibody Production for Immunoassay Diagnostics (RAPID) | 5/18/2026 |
| RFI: NMJ MPS Plarforms for BoNT Potency Assay (4/20/2026) | Request for Information: Neuromuscular Junction (NMJ) Micro-Physiological Systems for Botulinum Neurotoxin (BoNT) Potency Measurement and Medical Countermeasures Evaluation | 5/11/2026 |
| Request for Information: PreventARDS (4/1/2026) | Host Directed Therapeutics for the Prevention of Progression to ARDS | 4/15/2026 |
| RPP-26-07-ASSURE (11/14/2025) | Assay Development for Superior Understanding of Response and Efficacy (ASSURE) | 2/24/2026 |
| New Vaccine Platforms Request for Information (11/26/2025) | New Vaccine Platforms | 1/30/2026 |
| Rapid Antibody Production for Immunoassay Diagnostics (RAPID) Request for Information (10/31/2025) | Rapid Antibody Production | 12/4/2025 |
| RPP-26-09-AgDx (10/23/2025) | Agnostic Diagnostics | 11/20/2025 |
RPP-25-06-DxR2 | Biothreat Diagnostic Rapid Response | 8/4/2025 |
| RPP-24-07-CentralIEIDLab (5/7/2025) | Central Influenza and Emerging Infectious Diseases Vaccine Immunoassay Laboratory Services | 5/30/2025 |
| RPP-24-08-mRNALongTerm (08/30/2024) | Rapid Pandemic Influenza and Emerging Infectious Disease Vaccine Development and Response Capability | 2/28/2025 |
| RPP-24-02-OralVx (09/09/2024) | NextGen Oral Formulation Vaccines for COVID-19 | 11/15/2024 |
| RPP-24-02-ODM (08/13/2024) | On-Demand Manufacturing | 9/25/2024 |
| RPP-24-03-SmMol (08/05/2024) | COVID-19 Small Molecule Therapeutics for PrEP | 9/20/2024 |
| RPP-24-06-DxR2 (3/27/2024) | Biothreat Diagnostic Rapid Response | 5/17/2024 |
| RPP-24-03-Treatment (02/21/2024) | Project NextGen: Therapeutics | 5/13/2024 |
| RPP-24-05-NGClinMfg (01/16/2024) | Project NextGen: Innovation in Clinical Manufacturing of COVID-19 Vaccines | 4/19/2024 |
| RPP-24-04-NGVxStats (2/23/2024) | NextGen Vaccines: Statistical Support, Correlates of Protection, and Meta-analysis | 3/27/2024 |
| RPP-24-04-NGVxAssays (2/15/2024) | NextGen Vaccines: Immune Assays | 3/22/2024 |
| RPP-24-02-Retail (2/2/2024) | Enabling Technology – Decentralized Clinical Trial – Retail/Pharmacy Focus | 3/20/2024 |
| RPP-24-03-PrEP (11/30/2023) | COVID-19 Monoclonal Antibody Therapeutics for PrEP | 1/19/2024 |
| RPP-24-02-HomeFocus (11/30/2023) | Enabling Technology – Decentralized Clinical Trial – Home Focus | 1/19/2024 |
| RPP-24-04-NGVx (11/30/2023) | NextGen Vaccinations: Phase 2B Clinical Trial Execution | 1/10/2024 |
RPP-24-01-mRNA | Accelerating Near-Term Availability of mRNA-based Pandemic Influenza Vaccine | 12/4/2023 |